RxDoctor Payments Data

Renuka Patel, MD

Internal Medicine · Downey, CANPI 1467447904

Payments from drug & device makers

$1,473in general payments, 2019–2025

Across 64 payments — averaging $23.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$179
  • GSK$123
  • Astellas Pharma US Inc$121
  • AbbVie$114
  • Novo Nordisk$112
  • Lilly USA, LLC$100
  • plus $723 from 15 others

What the payments were for

  • Food & beverage$1,37393%
  • Education$1007%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,473 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$99,439
Medicare patients
231
Services billed
1,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin93$105,789
EliquisApixaban59$70,990
OzempicSemaglutide59$68,001
JanuviaSitagliptin Phosphate64$60,957
XareltoRivaroxaban51$48,408
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$32,241
FarxigaDapagliflozin Propanediol24$29,270
TrulicityDulaglutide18$25,882
EntrestoSacubitril/Valsartan18$24,584
JanumetSitagliptin Phos/Metformin Hcl23$20,927
MounjaroTirzepatide22$20,813
MyrbetriqMirabegron25$20,418
TradjentaLinagliptin20$10,769
KerendiaFinerenone15$9,789
Rasagiline Mesylate20$6,777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$96$116,559113 claims
MerckJanuvia, Janumet$14$81,88487 claims
PfizerEliquis$91$70,99059 claims
Novo NordiskOzempic$112$68,00159 claims
Lilly USA, LLCTrulicity, Mounjaro$100$46,69540 claims
GSKTrelegy Ellipta$123$32,24148 claims
AstraZenecaFarxiga$77$29,27024 claims
NovartisEntresto$37$24,58418 claims
Astellas Pharma US IncMyrbetriq$121$20,41825 claims
BayerKerendia$50$9,78915 claims
AbbVieSynthroid$114$5,90366 claims
Scilex Pharmaceuticals Inc.Colchicine$42$1,24812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Downey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →